Scorpion Therapeutics Presents Initial Clinical Data From Its Phase 1/2 Trial of STX-478 ... - KXRA
Scorpion Therapeutics presented initial Phase 1/2 data for STX-478, an oral, mutant-selective PI3Kα inhibitor, at ESMO 2024, showing anti-tumor activity in HR+/HER2- breast cancer, gynecological tumors, and other solid tumors, with potential best-in-class PI3Kα inhibition and minimal wild-type-mediated toxicities.
Related Clinical Trials
Reference News
Scorpion Therapeutics presented initial Phase 1/2 data for STX-478, an oral, mutant-selective PI3Kα inhibitor, at ESMO 2024, showing anti-tumor activity in HR+/HER2- breast cancer, gynecological tumors, and other solid tumors, with potential best-in-class PI3Kα inhibition and minimal wild-type-mediated toxicities.
Scorpion Therapeutics’ STX-478, a mutant-selective PI3Kα inhibitor, showed promising anti-tumor activity and tolerability in a Phase 1/2 trial, achieving an ORR of 23% in breast cancer and 21% across all tumor types. The drug demonstrated a good safety profile and potential in heavily pre-treated patients, presented at ESMO Congress 2024.